{"id":450387,"date":"2021-03-04T06:53:32","date_gmt":"2021-03-04T11:53:32","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=450387"},"modified":"2021-03-04T06:53:32","modified_gmt":"2021-03-04T11:53:32","slug":"protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/","title":{"rendered":"Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p \/>\n<p \/>\n<p>CARMIEL, <span class=\"xn-location\">Israel<\/span>, <span class=\"xn-chron\">March 4, 2021<\/span> \/PRNewswire\/ &#8212; Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx<sup>\u00ae<\/sup> plant cell\u2013based protein expression system, today announced today announced that the Company&#8217;s management will participate and present a corporate overview at the H.C.\u00a0Wainwright Global Life Sciences Conference, a virtual conference taking place March\u00a09\u201310, 2021.<\/p>\n<p>\u00a0<\/p>\n<div id=\"prni_dvprnejpg1eacleft\" dir=\"ltr\">\n        <img decoding=\"async\" id=\"prnejpg1eacleft\" title=\"Protalix Biotherapeutics Logo\" border=\"0\" alt=\"Protalix Biotherapeutics Logo\" align=\"middle\" src=\"https:\/\/mma.prnewswire.com\/media\/999479\/Protalix_Biotherapeutics_Logo.jpg\" \/>\n      <\/div>\n<p>\u00a0<\/p>\n<p>\n        <span class=\"xn-person\">Dror Bashan<\/span>, the Company&#8217;s President and Chief Executive Officer, has recorded a presentation that will be available beginning Tuesday, March\u00a09, 2021 at <span class=\"xn-chron\">7:00 am ET<\/span> at the following website: <a target=\"_blank\" href=\"http:\/\/tinyurl.com\/ftw6h8za\" rel=\"nofollow noopener noreferrer\">http:\/\/tinyurl.com\/ftw6h8za<\/a>. Those interested in registering for the conference can do so here: <a href=\"https:\/\/hcwevents.com\/globalconference\/\" rel=\"nofollow\">https:\/\/hcwevents.com\/globalconference\/<\/a>.<\/p>\n<p>A webcast of the presentation will also be available at <a target=\"_blank\" href=\"http:\/\/www.protalix.com\/\" rel=\"nofollow noopener noreferrer\">www.protalix.com<\/a> on the event calendar page, <a target=\"_blank\" href=\"https:\/\/protalixbiotherapeutics.gcs-web.com\/events0\" rel=\"nofollow noopener noreferrer\">https:\/\/protalixbiotherapeutics.gcs-web.com\/events0<\/a>. A replay of the presentation will be archived and available for approximately 90 days following the presentation.<\/p>\n<p>\n        <b>About Protalix BioTherapeutics, Inc.<\/b>\n      <\/p>\n<p>Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx<sup>\u00ae<\/sup>. Protalix was the first company to gain U.S.\u00a0Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix&#8217;s unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.<\/p>\n<p>Protalix&#8217;s first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the FDA in <span class=\"xn-chron\">May 2012<\/span> and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding <span class=\"xn-location\">Brazil<\/span>, where Protalix retains full rights.<\/p>\n<p>Protalix&#8217;s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human \u03b1\u2013Galactosidase\u2013A protein for the proposed treatment of Fabry disease; alidornase alfa or PRX\u2013110, for the treatment of various human respiratory diseases or conditions; PRX\u2013115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in <span class=\"xn-location\">the United States<\/span> and outside <span class=\"xn-location\">the United States<\/span>, for the development and commercialization of pegunigalsidase alfa, and with SarcoMed <span class=\"xn-location\">USA<\/span>, Inc. for the worldwide development and commercialization of PRX\u2013110 for use in the treatment<span>\u00a0<\/span>of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery.<\/p>\n<p>\n        <b>Investor Contact<\/b><br \/>\n        <br \/>\n        <span class=\"xn-person\">Chuck Padala<\/span>, Managing Director<br \/>LifeSci Advisors<br \/>+1-646-627-8390<br \/><a target=\"_blank\" href=\"mailto:chuck@lifesciadvisors.com\" rel=\"nofollow noopener noreferrer\">chuck@lifesciadvisors.com<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LN98034&amp;sd=2021-03-04\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/protalix-biotherapeutics-to-present-at-the-hc-wainwright-global-life-sciences-conference-301240443.html\">http:\/\/www.prnewswire.com\/news-releases\/protalix-biotherapeutics-to-present-at-the-hc-wainwright-global-life-sciences-conference-301240443.html<\/a><\/p>\n<p>SOURCE  Protalix BioTherapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LN98034&amp;Transmission_Id=202103040650PR_NEWS_USPR_____LN98034&amp;DateId=20210304\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire CARMIEL, Israel, March 4, 2021 \/PRNewswire\/ &#8212; Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx\u00ae plant cell\u2013based protein expression system, today announced today announced that the Company&#8217;s management will participate and present a corporate overview at the H.C.\u00a0Wainwright Global Life Sciences Conference, a virtual conference taking place March\u00a09\u201310, 2021. \u00a0 \u00a0 Dror Bashan, the Company&#8217;s President and Chief Executive Officer, has recorded a presentation that will be available beginning Tuesday, March\u00a09, 2021 at 7:00 am ET at the following website: http:\/\/tinyurl.com\/ftw6h8za. Those interested in registering for the conference can do so here: https:\/\/hcwevents.com\/globalconference\/. A webcast of the presentation will &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-450387","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire CARMIEL, Israel, March 4, 2021 \/PRNewswire\/ &#8212; Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx\u00ae plant cell\u2013based protein expression system, today announced today announced that the Company&#8217;s management will participate and present a corporate overview at the H.C.\u00a0Wainwright Global Life Sciences Conference, a virtual conference taking place March\u00a09\u201310, 2021. \u00a0 \u00a0 Dror Bashan, the Company&#8217;s President and Chief Executive Officer, has recorded a presentation that will be available beginning Tuesday, March\u00a09, 2021 at 7:00 am ET at the following website: http:\/\/tinyurl.com\/ftw6h8za. Those interested in registering for the conference can do so here: https:\/\/hcwevents.com\/globalconference\/. A webcast of the presentation will &hellip; Continue reading &quot;Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-04T11:53:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/999479\/Protalix_Biotherapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference\",\"datePublished\":\"2021-03-04T11:53:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\\\/\"},\"wordCount\":450,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/999479\\\/Protalix_Biotherapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\\\/\",\"name\":\"Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/999479\\\/Protalix_Biotherapeutics_Logo.jpg\",\"datePublished\":\"2021-03-04T11:53:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/999479\\\/Protalix_Biotherapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/999479\\\/Protalix_Biotherapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/","og_locale":"en_US","og_type":"article","og_title":"Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference - Market Newsdesk","og_description":"PR Newswire CARMIEL, Israel, March 4, 2021 \/PRNewswire\/ &#8212; Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx\u00ae plant cell\u2013based protein expression system, today announced today announced that the Company&#8217;s management will participate and present a corporate overview at the H.C.\u00a0Wainwright Global Life Sciences Conference, a virtual conference taking place March\u00a09\u201310, 2021. \u00a0 \u00a0 Dror Bashan, the Company&#8217;s President and Chief Executive Officer, has recorded a presentation that will be available beginning Tuesday, March\u00a09, 2021 at 7:00 am ET at the following website: http:\/\/tinyurl.com\/ftw6h8za. Those interested in registering for the conference can do so here: https:\/\/hcwevents.com\/globalconference\/. A webcast of the presentation will &hellip; Continue reading \"Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-04T11:53:32+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/999479\/Protalix_Biotherapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference","datePublished":"2021-03-04T11:53:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/"},"wordCount":450,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/999479\/Protalix_Biotherapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/","name":"Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/999479\/Protalix_Biotherapeutics_Logo.jpg","datePublished":"2021-03-04T11:53:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/999479\/Protalix_Biotherapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/999479\/Protalix_Biotherapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protalix-biotherapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Protalix BioTherapeutics to Present at the H.C. Wainwright Global Life Sciences Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/450387","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=450387"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/450387\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=450387"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=450387"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=450387"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}